Black Friday saleUp to 70% OFF

MRNA-1273

MRNA Moderna vaccine 94.5% effective in Phase 3 trial!This was my previews post about Moderna: The indicators are still bullish. The price of the stock grew 5X since the beginning of the year. 11/16/2020 Oppenheimer Boost Price Target ➝ $157.00 11/16/2020 Piper Sandler Boost Price Target ➝ $166.00 The traditional method of creating vaccines – introducing a weakened or dead virus, or a piece of one, to stimulate the body's immune system – takes over a decade on average, according to a 2013 study. One pandemic flu vaccine took over eight years while a hepatitis B vaccine was nearly 18 years in the making. Moderna's vaccine went from gene sequencing to the first human injection in 63 days. Moderna and BioNTech, for example, are also applying mRNA technology to experimental cancer medicines. BioNTech's vaccine, for example, must be transported at minus 70 degrees Celsius, though Moderna said on Monday it can ship its candidate in normal refrigerators. (Reuters) If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:MRNALong
by TopgOptions
Analysis on Moderna (Vaccine Company)Moderna (MRNA) is developing a COVID-19 vaccine candidate that is widely considered one of the frontrunners to bring a vaccine to market; it was the first company to share data about how its experimental vaccine performed in a Phase 1 clinical trial. It has so far soared more than 350% since the start of the year. The main reason is that there has been tremendous widespread investor interest on their vaccination project, and the obvious unmet need/opportunity for a COVID-19 vaccine. However, J.P. Morgan just recently downgraded the rating on Moderna (MRNA) and signal that its currently overvalued. I feel that if the price dips or there's any pullback, would be a good opportunity to enter for a short hold and probably selling it upon the next peak which I believe would be around their Phase 3 trials. Because long term hold on Moderna might be risky since more often than not, vaccines usually takes a long time before it actually gets released and for the company to be actually profitable.
NASDAQ:MRNALong
by Trader_hao
1
Weekly Rounded Top vs. +30% From the Low: look to long lower?Bullish: Every week since the low has closed green except this week. Bearish: The last week of each month have been particularly bearish since January. The overwhelming bull trend that's taken place over the past few weeks have been disorienting. My bias is now leaning neutral. I will consider the downtrend on hold if the monthly closes above the 17th of April high. Will switch bullish wiith a swiftness once issues with global oil pricing and the pandemic are resolved. Keeping an eye on the China/U.S. trade squabble. Black lines at the top/bottom are based on support/resistance levels and volume gaps. I should note that I am preferring the futures contract to chart for its longer session vs. the regular SPY chart or index. Recent oil news: Lack of available storage, due to it being so darn cheap to stock up on now, led to the dump of the front month futures contract. Oil also expires which explains why months further out are not as affected. www.bloomberg.com www.aljazeera.com www.wsj.com Recent coronavirus/COVID-19 news (only what could possibly be related to the markets' pricing): Possible vaccine, mRNA-1273, currently in human trials and stocks such as MRNA and GILD megapumped. Vaccines require time for trials/mass production, so it would be interesting to see how price would react the next time when a solid date on vaccine delivery is announced for...every country? I don't believe there's a globally accepted guideline on vaccine distribution. www.nasdaq.com time.com www.who.int Recent China/U.S. e-fight news: TBD There's a lot of articles out there without any proper coverage. Repeating old news in new publishments and talks related to the virus. The latter is important but oftentimes involves too much speculation and journalist bias.
CME_MINI:ES1!
by NeoButane